How Can We Stop Tumors from Shutting Down our Immune Response to Cancer?

By Staff Writer - December 05, 2022

Behind the Science is a video series featuring Moffitt Cancer Center clinicians and researchers spearheading novel therapies and groundbreaking treatments. You’ll get an up-close look at the innovative research being conducted every day.

LAG3 is a potent inhibitory receptor that sends an “off” signal to T cells. Under normal conditions, LAG3 prevents T cells from overreacting to infections. However, cancer cells can hijack the function of LAG3 to escape recognition by the immune system. Moffitt’s Dr. Vince Luca and his lab recently published novel data on the protein structure of these receptors and shares more with Dr. Patrick Hwu in the latest Behind the Science.

 

Subscribe

Most Popular